Compare Ascendis Pharma A/S (ASND) vs Uranium Energy Corp (UEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Uranium Energy Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Uranium Energy Corp trades at $10.41 (market cap $5.21B). The key difference: Ascendis Pharma A/S is far larger — about 3.4× Uranium Energy Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| ASND | UEC | |
|---|---|---|
Market Cap | $17.74B | $5.21B |
Sector | Health | Energy |
52-Week High | $277.18 | $20.14 |
52-Week Low | $163.32 | $6.59 |
Enterprise Value | $18.11B | $4.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
UEC trades at $10.53, up 3.64% today, but technical indicators show a bearish trend with strong selling pressure. The company reported widening losses with negative net income margins and zero revenue in recent quarters, though it maintains $794 million in liquid assets and no debt. Analyst consensus remains overwhelmingly bullish with 87.5% buy ratings, citing strategic positioning in uranium production.
Investment outlook hinges on execution of production ramp-ups and uranium price recovery. Key opportunities include strategic assets and strong liquidity, while risks involve persistent losses, regulatory delays, and volatile commodity prices. The stock faces near-term pressure from weak fundamentals despite long-term nuclear energy tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
